Form 4: NewAmsterdam Pharma Co N.V. Executive Receives Earnout Shares and RSUs Following Milestone Achievement

Johannes Jacob Pieter Kastelein, Chief Scientific Officer of NewAmsterdam Pharma Co N.V., reports acquisition of ordinary shares and restricted stock units (RSUs) related to a clinical development milestone achieved under the business combination agreement.

Summary

• Johannes Jacob Pieter Kastelein, the Chief Scientific Officer of NewAmsterdam Pharma Co N.V., has reported changes in beneficial ownership.
• On March 26, 2025, Kastelein acquired 19,302 ordinary shares and 45,481 RSUs as earnout shares and RSUs, respectively, pursuant to the business combination agreement (BCA).
• The earnout shares were issued to Futurum B.V. for Kastelein's benefit, and he exercises sole voting and investment control over these shares.
• The acquisition of shares and RSUs was triggered by the achievement of a clinical development milestone within five years of the closing date (November 22, 2022) of the BCA.
• Kastelein also converted 45,481 RSUs into ordinary shares on the same date.
• Following these transactions, Kastelein directly owns 79,481 ordinary shares and indirectly owns 169,302 ordinary shares through Futurum B.V.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects the achievement of a clinical milestone, triggering the issuance of earnout shares and RSUs. This suggests progress in the company's development pipeline and aligns management incentives with shareholder value.

Positives

• The achievement of the clinical development milestone is a positive indicator of the company's progress.
• The issuance of earnout shares and RSUs to key personnel like the Chief Scientific Officer aligns their interests with the company's success.
• Kastelein's increased stake in the company demonstrates his confidence in its future prospects.

Future Outlook

The document does not contain specific forward-looking statements beyond the implications of achieving the clinical development milestone.

Industry Context

In the pharmaceutical industry, achievement of clinical milestones is a critical value driver, often triggering pre-defined payouts or equity grants to incentivize key personnel. This filing reflects the successful attainment of such a milestone by NewAmsterdam Pharma.

Comparison to Industry Standards

• Equity-based compensation and earnout structures are common in the pharmaceutical industry, particularly following mergers or acquisitions, to align management incentives with long-term value creation.
• Comparable companies often use similar milestone-based equity grants to incentivize the achievement of clinical trial objectives and regulatory approvals.
• The specific terms of the BCA, including the formula for determining the number of earnout shares and RSUs, would need to be compared to industry benchmarks to assess its relative generosity or stringency.

Stakeholder Impact

• Shareholders may view the achievement of the clinical milestone positively, potentially leading to an increase in the company's stock price.
• Employees, particularly key personnel like the Chief Scientific Officer, benefit from the issuance of earnout shares and RSUs, aligning their interests with the company's success.

Key Dates

Keywords

NewAmsterdam Pharma, Kastelein, Earnout Shares, RSUs, Clinical Milestone, Beneficial Ownership, Form 4, NAMS, Business Combination Agreement